Brokerages Set ICON PLC (NASDAQ:ICLR) Target Price at $96.00

ICON PLC (NASDAQ:ICLR) has received a consensus recommendation of “Buy” from the twelve research firms that are covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $108.00.

A number of research firms have commented on ICLR. Zacks Investment Research downgraded shares of ICON PLC from a “hold” rating to a “sell” rating in a report on Wednesday, April 26th. ValuEngine downgraded shares of ICON PLC from a “buy” rating to a “hold” rating in a report on Wednesday, May 31st. Jefferies Group LLC upgraded shares of ICON PLC from a “hold” rating to a “buy” rating and increased their price objective for the company from $86.00 to $117.00 in a report on Thursday, June 29th. BidaskClub upgraded shares of ICON PLC from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Finally, Credit Suisse Group reiterated an “outperform” rating and issued a $102.00 price objective (up previously from $91.00) on shares of ICON PLC in a report on Tuesday, June 6th.

Institutional investors have recently modified their holdings of the stock. Shine Investment Advisory Services Inc. acquired a new position in shares of ICON PLC during the second quarter valued at approximately $103,000. Acrospire Investment Management LLC boosted its position in shares of ICON PLC by 20.1% in the second quarter. Acrospire Investment Management LLC now owns 1,195 shares of the medical research company’s stock valued at $117,000 after buying an additional 200 shares in the last quarter. Parallel Advisors LLC boosted its position in shares of ICON PLC by 20.7% in the second quarter. Parallel Advisors LLC now owns 1,265 shares of the medical research company’s stock valued at $133,000 after buying an additional 217 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its position in shares of ICON PLC by 27.2% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,460 shares of the medical research company’s stock valued at $111,000 after buying an additional 312 shares in the last quarter. Finally, Huntington National Bank boosted its position in shares of ICON PLC by 5.0% in the second quarter. Huntington National Bank now owns 1,630 shares of the medical research company’s stock valued at $159,000 after buying an additional 77 shares in the last quarter. 92.55% of the stock is owned by institutional investors.

ICON PLC (NASDAQ ICLR) opened at 101.40 on Monday. The stock has a market cap of $5.48 billion, a PE ratio of 20.57 and a beta of 0.60. ICON PLC has a 12 month low of $73.76 and a 12 month high of $109.32. The company’s 50 day moving average price is $100.50 and its 200 day moving average price is $89.05.

ICON PLC (NASDAQ:ICLR) last issued its quarterly earnings results on Thursday, July 27th. The medical research company reported $1.31 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.30 by $0.01. The firm had revenue of $431 million for the quarter, compared to analyst estimates of $430.68 million. ICON PLC had a net margin of 15.97% and a return on equity of 28.72%. ICON PLC’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period last year, the company posted $1.14 EPS. Equities analysts forecast that ICON PLC will post $5.32 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Brokerages Set ICON PLC (NASDAQ:ICLR) Target Price at $96.00” was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.com-unik.info/2017/08/12/icon-plc-nasdaqiclr-receives-consensus-rating-of-buy-from-analysts-updated-updated-updated.html.

ICON PLC Company Profile

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Analyst Recommendations for ICON PLC (NASDAQ:ICLR)

What are top analysts saying about ICON PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ICON PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit